Swipe om te navigeren naar een ander artikel
This study aimed to describe rates of antipsychotic medication use and the association between their use and demographics, clinical variables, and the use of behavioral/education services among children with ASD. For children with ASD ages 2–11 (n = 4749) and those 12–17 (n = 401), 5.4 and 17.7% were prescribed at least one atypical antipsychotic medication respectively. In the multivariable model of young children, older age, use of multiple psychotropic medications, prior ASD diagnosis, non-white Hispanic race/ethnicity, and oppositional defiant problems were associated with antipsychotic use. Among older children, only older age was associated with antipsychotic use. In at least one age group, antipsychotic medication use was also related to behaviour, family and occupational therapy, public insurance, site region, externalizing problems, body mass index, and sleep and gastrointestinal problems.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Achenbach, T. M., & Rescorla, L. A. (2000). Manual for the ASEBA Preschool forms and Profiles. Burlington, VT: University of Vermont Department of Psychiatry.
Almandil, N. B., Liu, Y., Murray, M. L., Besag, F. M., Aitchison, K. J., & Wong, I. C. (2013). Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis. Pediatric Drugs, 15(2), 139–50. CrossRefPubMed
Aman, M. G., McDougle, C. J., Scahill, L., Handen, B., Arnold, L. E., Johnson, C., … & Wagner, A. (2009). Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 48, 1143–54. CrossRefPubMed
Frazier, T. W., Shattuck, P. T., Narendorf, S. C., Cooper, B. P., Wagner, M., & Spitznagel, E. L. (2011). Prevalence and correlates of psychotropic medication use in adolescents with an autism spectrum disorder with and without caregiver-reported attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 21(6), 571–79. CrossRefPubMedPubMedCentral
Frazier, T. W., Youngstrom, E. A., Haycook, T., Sinoff, A., Dimitriou, F., Knapp, J., & Sinclair, L. (2010). Effectiveness of medication combined with intensive behavioral intervention for reducing aggression in youth with autism spectrum disorder. Journal of Child and Adolescent Psychopharmacology, 20(3), 167–77. CrossRefPubMed
Gleason, M. M., Egger, H. L., Emslie, G. J., Greenhill, L. L., Kowatch, R. A., Lieberman, A. F., ... & Zeanah, C. H. (2007). Psychopharmacological treatment for very young children: Contexts and guidelines. Journal of the American Academy of Child & Adolescent Psychiatry, 46, 1532–72. CrossRef
Hassiotis, A., Robotham, D., Canagasabey, A., Romeo, R., Langridge, D., Blizard, R., Murad, S., & King, M. (2009). Randomized, single-blind, controlled trial of a specialist behavior therapy team for challenging behavior in adults with intellectual disabilities. The American Journal of Psychiatry, 166, 1278–85. CrossRefPubMed
Jensen, P. S., Hinshaw, S. P., Swanson, J. M., Greenhill, L. L., Conners, C. K., Arnold, L. E., ... & March, J. S. (2001). Findings from the NIMH multimodal treatment study of ADHD (MTA): Implications and applications for primary care providers. Journal of Developmental & Behavioral Pediatrics, 22(1), 60–73. CrossRef
Lòpez-De Fede, A., Vyavaharkar, M., & Bellinger, J. D. (2014). Antipsychotic prescriptions for children aged 5 years or younger. SAGE Open, 4(4), 2158244014555116. CrossRef
Mandell, D. S., Morales, K. H., Marcus, S. C., Stahmer, A. C., Doshi, J., & Polsky, D. E. (2008). Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics, 121, 441–48. CrossRef
Martínez-Ortega, J. M., Funes-Godoy, S., Díaz-Atienza, F., Gutiérrez-Rojas, L., Pérez-Costillas, L., & Gurpegui, M. (2013). Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review. European Child & Adolescent Psychiatry, 22(8), 457–79. CrossRef
Medicaid Medical Directors Learning Network. (2010). Antipsychotic medication use in medicaid children and adolescents: Report and resource guide from a 16-state study. Medicaid medical directors learning network and rutgers center for education and research on mental health therapeutics. Retrieved from: http://rci.rutgers.edu/~cseap/ MMDLNAPKIDS.html.
National Institute for Health and Care Excellence. (2014). NICE quality standard 51. guidance.nice.org.uk/qs51.
Owens, J. A., Spirito, A., & McGuinn, M. (2000). The Children’s sleep habits questionnaire (CSHQ): Psychometric properties of a survey instrument for school-aged children. Sleep, 23(8), 1043–51. PubMed
Park, S. Y., Cervesi, C., Galling, B., Molteni, S., Walyzada, F., Ameis, S. H., ... & Correll, C. U. (2016). Antipsychotic use trends in youth with autism spectrum disorder and/or intellectual disability: A meta-analysis. Journal of the American Academy of Child & Adolescent Psychiatry, 55(6), 456–68. CrossRef
Peters, B., Williams, K. C., Gorrindo, P., Rosenberg, D., Lee, E. B., Levitt, P., & Veenstra-VanderWeele, J. (2014). Rigid–compulsive behaviors are associated with mixed bowel symptoms in autism spectrum disorder. Journal of Autism and Developmental Disorders, 44(6), 1425–32. CrossRefPubMedPubMedCentral
Volkmar, Fred, et al. (2014). Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 53(2), 237–57. CrossRef
Yen, J., Grover, M., & Mao, A. (2011). Antipsychotics and autism: Weight, metabolism, and safety. Child and Adolescent Psychopharmacology News, 16(1), 1–11. CrossRef
- Medical Conditions and Demographic, Service and Clinical Factors Associated with Atypical Antipsychotic Medication Use Among Children with An Autism Spectrum Disorder
Johanna K. Lake
Amy M. Shui
- Springer US